About Us

Dr. Enas A. Enas, MD, FACC

Founding President & CEO, CADI Research Foundation

Dr. Enas A. Enas is a world-renowned cardiologist and leading authority on heart disease in people of Indian origin. Founder of the nonprofit CADI Research Foundation, he has dedicated more than five decades to combating premature coronary artery disease in this high-risk group.

As principal investigator of the landmark 1996 CADI Study, he demonstrated that Indian Americans face more than double the heart disease rates of the general population—a finding later confirmed in the UK, independent of diabetes, hypertension, cholesterol, and tobacco. He was also the first to identify lipoprotein(a) [Lp(a)] as a key genetic driver and pioneered early, aggressive statin use in South Asians.

Read more
Dr. Enas has led major international initiatives, including three International Working Group meetings on Cardio Vascular Disease CVD in South Asians and the first two Indo-US Health Summits. He has authored more than 100 publications and two major books: the 2005 bestseller How to Beat the Heart Disease Epidemic among South Asians (2005) and Treatise on Heart Disease in Indians (2025), his magnum opus distilling 50 years of research.

His work helped shape the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines, which now recognize South Asian ethnicity and elevated Lp(a) as important ASCVD risk enhancers. His honors include being named America’s Top Cardiologist in Preventive Cardiology by the Consumers’ Research Council of America every year since 2009, as well as receiving the Most Distinguished Physician Award from the American Association of Physicians of Indian Origin (AAPI) and the Master Award from the Association of Kerala Medical Graduates (AKMG) in the United States.

A graduate of the University of Kerala and trained in cardiology at Cook County Hospital, Chicago, Dr. Enas is a Fellow of the American College of Cardiology and a member of the American Medical Association (AMA) and AHA. He is also a strong global advocate for the “polypill” (a statin plus two blood pressure drugs), projected to prevent 72 million deaths and 130 million nonfatal cardiovascular events worldwide by 2050.